This study has demonstrated the ability of simvastatin to suppress Th17 cytokines (IL-17 and IL-22), CXCL8, and IL-6, with concomitant enhancement of IL-10 production and IDO expression and activity in patients with COPD. Here, IL22 is linked to chronic obstructive pulmonary disease.